Effects of propranolol in patients with central serous chorioretinopathy

<ul> <li><strong>BACKGROUND</strong>: Central serous retinopathy (CSR) is a frequent disease often involves healthy men and causes visual disturbances. This study was undertaken to investigate the effects of propranolol tablet on improvement of...

Full description

Bibliographic Details
Main Authors: Farzan Kianersi, Farnaz Fesharaki
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2008-06-01
Series:Journal of Research in Medical Sciences
Subjects:
Online Access:http://journals.mui.ac.ir/jrms/article/view/1124
_version_ 1818491527143358464
author Farzan Kianersi
Farnaz Fesharaki
author_facet Farzan Kianersi
Farnaz Fesharaki
author_sort Farzan Kianersi
collection DOAJ
description <ul> <li><strong>BACKGROUND</strong>: Central serous retinopathy (CSR) is a frequent disease often involves healthy men and causes visual disturbances. This study was undertaken to investigate the effects of propranolol tablet on improvement of CSR in referral cases to Farabi and Feiz hospitals in Isfahan in 2003-2004.</li> <li><strong>METHODS</strong>: This was a double-blind randomized controlled clinical trial. Patients with CSR referred to Farabi and Feiz hospitals were randomly divided into 2 groups: treatment group and control group, each one included 30 patients. Treatment group took propranolol tablets 20 mg twice a day, and control group took placebo tablets. Patients were examined weekly until complete improvement. Means of duration of disease and final visual acuity on the basis of lag mar were compared by t-test. Relative frequency of final visual acuity of 10/10 in the two groups was compared using chisquare tests.</li> <li><strong>RESULTS</strong>: Two groups were comparable with respect to age, sex, involved eye, psychological tensions and clinical findings. The course of improvement in treatment group was 62 ± 29 days and in control group was 89 ± 44 days (P < 0.05). Means of final visual acuities were not significantly different between the two groups (0.98 ± 0.13 log mar in treatment group compared to 0.97 ± 0.18 log mar in control group). Relative frequency of vision < 10/10 was 30% in control group and 3.3% in treatment group (P < 0.01).</li> <li><strong>CONCLUSION</strong>: Duration of disease and need to laser therapy in patients with CSR were decreased by the use of propranolol but it had no effect on the amount of final vision. Because the patients are mostly in the years of active life, propranolol use is recommended for these patients.</li> <li><strong>KEYWORDS</strong>: Central serous chorioretinopathy, visual acuity, propranolol.</li> </ul>
first_indexed 2024-12-10T17:32:12Z
format Article
id doaj.art-c5b7a4ff124547dfbbf06c42b261970a
institution Directory Open Access Journal
issn 1735-1995
1735-7136
language English
last_indexed 2024-12-10T17:32:12Z
publishDate 2008-06-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Research in Medical Sciences
spelling doaj.art-c5b7a4ff124547dfbbf06c42b261970a2022-12-22T01:39:39ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362008-06-01133103107Effects of propranolol in patients with central serous chorioretinopathyFarzan KianersiFarnaz Fesharaki<ul> <li><strong>BACKGROUND</strong>: Central serous retinopathy (CSR) is a frequent disease often involves healthy men and causes visual disturbances. This study was undertaken to investigate the effects of propranolol tablet on improvement of CSR in referral cases to Farabi and Feiz hospitals in Isfahan in 2003-2004.</li> <li><strong>METHODS</strong>: This was a double-blind randomized controlled clinical trial. Patients with CSR referred to Farabi and Feiz hospitals were randomly divided into 2 groups: treatment group and control group, each one included 30 patients. Treatment group took propranolol tablets 20 mg twice a day, and control group took placebo tablets. Patients were examined weekly until complete improvement. Means of duration of disease and final visual acuity on the basis of lag mar were compared by t-test. Relative frequency of final visual acuity of 10/10 in the two groups was compared using chisquare tests.</li> <li><strong>RESULTS</strong>: Two groups were comparable with respect to age, sex, involved eye, psychological tensions and clinical findings. The course of improvement in treatment group was 62 ± 29 days and in control group was 89 ± 44 days (P < 0.05). Means of final visual acuities were not significantly different between the two groups (0.98 ± 0.13 log mar in treatment group compared to 0.97 ± 0.18 log mar in control group). Relative frequency of vision < 10/10 was 30% in control group and 3.3% in treatment group (P < 0.01).</li> <li><strong>CONCLUSION</strong>: Duration of disease and need to laser therapy in patients with CSR were decreased by the use of propranolol but it had no effect on the amount of final vision. Because the patients are mostly in the years of active life, propranolol use is recommended for these patients.</li> <li><strong>KEYWORDS</strong>: Central serous chorioretinopathy, visual acuity, propranolol.</li> </ul>http://journals.mui.ac.ir/jrms/article/view/1124Central serous chorioretinopathy, visual acuity, propranolol.
spellingShingle Farzan Kianersi
Farnaz Fesharaki
Effects of propranolol in patients with central serous chorioretinopathy
Journal of Research in Medical Sciences
Central serous chorioretinopathy, visual acuity, propranolol.
title Effects of propranolol in patients with central serous chorioretinopathy
title_full Effects of propranolol in patients with central serous chorioretinopathy
title_fullStr Effects of propranolol in patients with central serous chorioretinopathy
title_full_unstemmed Effects of propranolol in patients with central serous chorioretinopathy
title_short Effects of propranolol in patients with central serous chorioretinopathy
title_sort effects of propranolol in patients with central serous chorioretinopathy
topic Central serous chorioretinopathy, visual acuity, propranolol.
url http://journals.mui.ac.ir/jrms/article/view/1124
work_keys_str_mv AT farzankianersi effectsofpropranololinpatientswithcentralserouschorioretinopathy
AT farnazfesharaki effectsofpropranololinpatientswithcentralserouschorioretinopathy